Colitis is an inflammation of the colon. Colitis may be acute and self-limited or long-term. It broadly fits into the category of digestive diseases. Colitis Pipeline Market Research Report provides the latest projects and drug profiles with key companies.
Introduction:
Colitis is swelling (inflammation) of the large intestine (colon). Colitis can have many different causes, including infections, including those caused by a virus, parasite, and food poisoning due to bacteria, inflammatory disorders (ulcerative colitis and Crohn's disease), lack of blood flow (ischemic colitis), past radiation to the large bowel). Symptoms can include abdominal pain, bloating, bloody stools, chills, dehydration, diarrhea and fever. Treatment includes non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids.
Get Discount on this Research Report at http://www.reportsnreports.com/contacts/discount.aspx?name=911458 .
The Pharmaceutical and Healthcare latest pipeline guide Colitis Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Colitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Key Company Profiles:
Akebia Therapeutics Inc, Bristol-Myers Squibb Company, Concenter BioPharma Silkim Ltd, Cosmo Pharmaceuticals NV, CSA Biotechnologies LLC, Dr. Falk Pharma GmbH, EA Pharma Co Ltd, Genfit SA, Immuron Ltd, Innate Pharma SA, Ogeda SA, Peptinov SAS, Pfizer Inc, RDD Pharma Ltd, Saniona AB, Sigmoid Pharma Ltd, Soligenix Inc, Synovo GmbH.
Colitis - Drug Profiles:
AcTMP-1 - Drug Profile, AKB-6899 - Drug Profile, AN-346 - Drug Profile, Antibody for Colitis - Drug Profile, Antisense RNAi Oligonucleotides to Inhibit TNFalpha for Inflammatory Diseases and Colitis, APY-0201 - Drug Profile, BC-1215 - Drug Profile, BMS-986104 - Drug Profile, budesonide - Drug Profile, CSA-13 - Drug Profile, CSY-0073 - Drug Profile, dimethyloxalylglycine - Drug Profile, Drugs to Antagonize TRP Channel for Inflammatory Diseases and Colitis - Drug Profile, dusquetide - Drug Profile, elafibranor - Drug Profile, ESN-601 - Drug Profile, IMM-124E - Drug Profile, IPH-33 - Drug Profile, NK-007 - Drug Profile, Peptide to Inhibit NFkB for Colitis and Enteritis - Drug Profile, PF-06425090 - Drug Profile, PPV-06, RDD-2007 - Drug Profile.

Inquire more on this Research Report at http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=911458
Colitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
The pipeline guide provides a snapshot of the global therapeutic landscape of Colitis (Gastrointestinal).
The pipeline guide reviews pipeline therapeutics for Colitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
The pipeline guide reviews key companies involved in Colitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
The pipeline guide evaluates Colitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
The pipeline guide reviews latest news related to pipeline therapeutics for Colitis (Gastrointestinal)
Purchase this research report Direct from http://www.reportsnreports.com/purchase.aspx?name=911458 .
Table of Contents:
Colitis - Overview
Colitis - Therapeutics Development
Colitis Pipeline Overview
Colitis Pipeline by Companies
Colitis - Therapeutics Assessment
Colitis - Companies Involved in Therapeutics Development
Colitis - Drug Profiles
Colitis - Dormant Projects
Colitis - Product Development Milestones and more…

List of Tables.
Number of Products under Development for Colitis, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Stage and Target, H1 2017
Colitis - Pipeline by Pfizer Inc, H1 2017
Colitis - Pipeline by Saniona AB, H1 2017
Colitis - Pipeline by Soligenix Inc, H1 2017
Colitis - Dormant Projects, H1 2017 and more…

About Us:
ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. Order report by calling ReportsnReports.com at +1 888 391 5441 OR send an email on [email protected] with your contact details.